Presentation is loading. Please wait.

Presentation is loading. Please wait.

Gene Copy Number Aberrations Are Associated with Survival in Histologic Subgroups of Non-small Cell Lung Cancer  Patrick Micke, MD, PhD, Karolina Edlund,

Published byKarina Kari Rasmussen Modified over 5 years ago

Similar presentations

Presentation on theme: "Gene Copy Number Aberrations Are Associated with Survival in Histologic Subgroups of Non-small Cell Lung Cancer  Patrick Micke, MD, PhD, Karolina Edlund,"— Presentation transcript:

1 Gene Copy Number Aberrations Are Associated with Survival in Histologic Subgroups of Non-small Cell Lung Cancer  Patrick Micke, MD, PhD, Karolina Edlund, BSc, Lars Holmberg, MD, PhD, Hanna Göransson Kultima, BSc, Larry Mansouri, PhD, Simon Ekman, MD, PhD, Michael Bergqvist, MD, PhD, Lena Scheibenflug, MD, Kristina Lamberg, MD, Gunnar Myrdal, MD, PhD, Anders Berglund, BSc, Annsofie Andersson, MSc, Mats Lambe, MD, PhD, Fredrik Nyberg, MD, PhD, Andrew Thomas, PhD, Anders Isaksson, PhD, Johan Botling, MD, PhD  Journal of Thoracic Oncology  Volume 6, Issue 11, Pages (November 2011) DOI: /JTO.0b013e Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1. Global gene copy number analysis of 100 NSCLC cases using Affymetrix GeneChip 250K SNP arrays. Frequencies of gene copy number gains (green) and losses (red) for all 100 samples and for the 50 adenocarcinomas, 22 large-cell carcinomas, and 28 squamous cell carcinomas separately. NSCLC, non-small cell lung cancer; SNP, single-nucleotide polymorphism. Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e ) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2. Global gene copy number analysis of 50 adenocarcinoma cases using Affymetrix GeneChip 250K SNP arrays. Comparison plot contrasting patients with long (≥58 months) versus short (≤20 months) survival time. Gains on chromosome 8q were more frequent in patients with long-term survival than in patients with short time survival. The region 8q comprises 177 genes. SNP, single-nucleotide polymorphism. Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e ) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3. Global gene copy number analysis of 28 squamous cell carcinoma cases using Affymetrix GeneChip 250K SNP arrays. Comparison plot contrasting patients with long (≥58 months) versus short (≤20 months) survival time. Genetic gains on chromosome 14q were associated with shorter survival: (139 genes) and losses on 14q (110 genes; frequency 0% versus 33%) with favorable outcome. SNP, single-nucleotide polymorphism. Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e ) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Gene Copy Number Aberrations Are Associated with Survival in Histologic Subgroups of Non-small Cell Lung Cancer  Patrick Micke, MD, PhD, Karolina Edlund,"

Similar presentations

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.
MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort  Michèle Beau-Faller, MD,

MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort  Michèle Beau-Faller, MD,
Su K. Metcalfe, MD, MPH, Michael T

Su K. Metcalfe, MD, MPH, Michael T
Naomi Fujioka, MD, Christopher A. French, MD, Michael J

Naomi Fujioka, MD, Christopher A. French, MD, Michael J
A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,
Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,
Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus  Yang Zhao, MD, ZhiJun Dai,

Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus  Yang Zhao, MD, ZhiJun Dai,
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
SC17.02 Lung Cancer in China: Challenges and Perspectives

SC17.02 Lung Cancer in China: Challenges and Perspectives
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.
Timon P. H. Buys, BSc, Sarit Aviel-Ronen, MD, Thomas K

Timon P. H. Buys, BSc, Sarit Aviel-Ronen, MD, Thomas K
APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26
Results of Surgical Treatment for Patients with Small Cell Lung Cancer

Results of Surgical Treatment for Patients with Small Cell Lung Cancer
Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer  David R. Gandara, MD,

Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer  David R. Gandara, MD,
Yih-Leong Chang, MD, Chen-Tu Wu, MD, Yung-Chie Lee, MD, PhD 

Yih-Leong Chang, MD, Chen-Tu Wu, MD, Yung-Chie Lee, MD, PhD 
A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,

Similar presentations

Ads by Google